Brief: Inventiva Announces Positive Results Of Clinical Thorough QT Study Conducted With Lanifibranor
06/12/2021 21:04
Dec 6 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES POSITIVE RESULTS OF CLINICAL THOROUGH
QT
STUDY CONDUCTED WITH LANIFIBRANOR
* INVENTIVA - LANIFIBRANOR ADMINISTERED AT ANTICIPATED
MAXIMAL
THERAPEUTIC DOSE OF 1200MG/DAY AND AT SUPRA-THERAPEUTIC DOSE OF
2400MG/DAY HAD NO IMPACT ON QT/QTC INTERVAL
* INVENTIVA SA - LANIFIBRANOR WAS WELL TOLERATED AT BOTH
DOSE
LEVELS
Source text for Eikon: ID:nGNX74gQzB
Further company coverage: IVAA.PA
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030